Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20780290 | 0.81 | MMP1 (0.32) | CA14KCNA5 | |
| SCHEMBL11344592 | 0.74 | ALDH1A1 (0.33) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL12988855 | 0.74 | TSHR (0.46) | CA14BCHEALDH1A1CA12HCAR2 | |
| SCHEMBL304772 | 0.74 | BCHE (0.33) | BCHE | |
| SCHEMBL3636117 | 0.74 | — | — | |
| SCHEMBL25477680 | 0.74 | BCHE (0.33) | BCHE | |
| SCHEMBL16965826 | 0.74 | TSHR (0.33) | BCHE | |
| SCHEMBL3526460 | 0.74 | BCHE (0.36) | BCHEALDH1A1 | |
| SCHEMBL5921933 | 0.74 | — | — | |
| SCHEMBL8985024 | 0.74 | BCHE (0.33) | BCHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687490-B2 | 2-thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2010-03-30 | — | — | US | claimed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | claimed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | claimed |
| US-12194020-B2 | Reversing baldness through cannabinoid receptor activation | POSTREL RICHARD (US) | 2025-01-14 | — | — | US | disclosed |
| CN-114736219-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-114751920-B | Antitumor compounds | 法马马有限公司 | 2024-06-07 | — | — | CN | disclosed |
| CN-117865987-A | Antitumor compounds | 法马马有限公司 | 2024-04-12 | — | — | CN | disclosed |
| WO-2024073626-A2 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023125928-A1 | MENIN INHIBITOR AND USE THEREOF | 成都先导药物开发股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-20220249434-A1 | Reversal of Baldness in Men and Women through Cannabinoid Receptor Activation | POSTREL RICHARD (US) | 2022-08-11 | — | — | US | disclosed |
| EP-1870412-A1 | 2-THIOETHENYL CARBAPENEM DERIVATIVE | MEIJI SEIKA KAISHA LTD. (JP) | 2007-12-26 | — | — | EP | disclosed |
| US-20070117839-A1 | Two cyclic cinnamide compound | EISAI R&D MANAGEMENT CO., LTD. | 2007-05-24 | — | — | US | disclosed |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-01-04 | — | — | US | disclosed |
| US-20060160802-A1 | Peptide deformylase inhibitors | GLAXO GROUP LIMITED | 2006-07-20 | — | — | US | disclosed |
| WO-2005005456-A2 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
| CN-1127502-C | Paroxetine methanesulfonate | SMITHKLINE BEECHAM PLC (GB) | 2003-11-12 | — | — | CN | disclosed |
| CN-1315949-A | Salts of paroxetine | SMITHKLINE BEECHAM PLC (GB) | 2001-10-03 | — | — | CN | disclosed |
| US-5223633-A | Deprotonating a carbamate; chelation with diamine; removal of protecting group | BAYER AKTIENGESELLSCHAFT (DE) | 1993-06-29 | — | — | US | disclosed |
| EP-0478076-A2 | Processes for the preparation of hydroxyl-containing compounds | UNION CARBIDE CHEMICALS AND PLASTICS COMPANY, INC. (US) | 1992-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | ADORA2A, ADORA1, ADORA2B | CA14 2921/4885BCHE 1425/4885ALDH1A1 342/4885 |
| US-20070004700-A1 | 2-Thioethenyl substituted carbapenem derivatives | MTAP, BLVRB, BPGM | CA14 2099/4885BCHE 25/4885ALDH1A1 1182/4885 |
| US-20070117839-A1 | Two cyclic cinnamide compound | APP, BACE1, PSEN1 | CA14 4499/4885BCHE 526/4885ALDH1A1 869/4885 |
| US-20060160802-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | CA14 4836/4885BCHE 3091/4885ALDH1A1 4302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.